Read the findings & sources
Human study discussedA randomized 26-week trial in 412 people with HIV-associated abdominal fat accumulation reported a 15.2% reduction in visceral fat with tesamorelin, versus a 5.0% increase with placebo. This was an imaging measure of internal abdominal fat, not a 15.2% reduction in body weight. IGF-1 also increased; the findings do not establish a general weight-loss or anti-aging effect in healthy adults.